 <h1>Enfortumab vedotin Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to enfortumab vedotin: parenteral powder for injection</i></p><p>Side effects include:</p><p>Fatigue, peripheral neuropathy, decreased appetite, rash, alopecia, nausea, dysgeusia, diarrhea, dry eye, pruritus, dry skin, anemia, lymphopenia, hypophosphatemia, elevated concentrations of lipase, hyperglycemia, hyponatremia, hyperuricemia, neutropenia. </p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to enfortumab vedotin: intravenous powder for injection</i></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Hemoglobin decreased (34%), lymphocytes decreased (32%), neutrophils decreased (14%), leukocytes decreased (14%)<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Extravasation (e.g., erythema, swelling, increased temperature, pain), secondary cellulitis, bullae, exfoliation</p><p><b>Frequency not reported</b>: Possible immunogenicity<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Very common</b> (10% or more): Ocular disorders (e.g., keratitis, blurred vision, limbal stem cell deficiency) (46%), dry eye (e.g., blepharitis, conjunctivitis, dry eye, eye irritation, keratitis, keratopathy, lacrimation increased, limbal stem cell deficiency, Meibomian gland dysfunction, ocular discomfort, punctate keratitis, tear break up time decreased) (36%), blurred vision (14%), dysgeusia (42%)<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Decreased appetite (52%), phosphate decreased (34%), potassium decreased (19%), lipase increased (14%)</p><p><b>Common</b> (1% to 10%): Glucose increased, sodium decreased, urate increased<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue/asthenia (56%)<sup>[Ref]</sup></p><h3>General</h3><p>The most common adverse reactions (20% or greater) included fatigue, peripheral neuropathy, decreased appetite, rash, alopecia, nausea, dysgeusia, diarrhea, dry eye, pruritus and dry skin.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Peripheral neuropathy (e.g., hypoesthesia, gait disturbance, muscular weakness, neuralgia, paresthesia, peripheral motor neuropathy, peripheral sensory neuropathy, peripheral sensorimotor neuropathy) (56%)<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Creatinine increased (20%)<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (e.g., dermatitis acneiform, dermatitis contact, dermatitis exfoliative, drug eruption, erythema, erythema multiforme, photosensitivity reaction, rash, rash erythematous, rash generalized, rash macular, rash papular, rash pustular, rash pruritic, rash vesicular, skin exfoliation, stasis dermatitis, urticaria (52%), alopecia (50%), pruritus (30%), maculopapular rash (26%), dry skin (26%), symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) (10%), bullous dermatitis (10%), exfoliative dermatitis (10%), palmar-plantar erythrodysesthesia (10%)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (45%), diarrhea (e.g., colitis, diarrhea, enterocolitis) (42%), vomiting (18%)<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Padcev (enfortumab vedotin)." Seattle Genetics Inc, Bothell, WA. </p><h2>More about enfortumab vedotin</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>1 Review</li>
<li>Drug class: miscellaneous antineoplastics</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Enfortumab vedotin-ejfv Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Urothelial Carcinoma</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>